Shares of Biogen BIIB rose nearly 5% yesterday after the company announced that the FDA approved a subcutaneous (SC) ...

The most common side effects of IV lecanemab are headache, infusion-related reactions, and amyloid-related imaging abnormalities, a side effect known to occur with the class of an ...

Lecanemab decision marks first time patients can begin treatment with home administration ...

Eisai and Biogen have announced that the U.S. Food and Drug Administration has approved a supplemental biologics licence application for a once weekly subcutaneous initiation dose ...

FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference (AAIC), held in London, July 12-15, demonstrating ...

Sanofi has scored FDA approval for its subcutaneous version of Sarclisa, giving the multiple myeloma treatment a potential ...

The FDA has approved a subcutaneous version of isatuximab (Sarclisa Escena, Sanofi-Aventis) for several multiple myeloma (MM) ...

Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena ...

Your subcutaneous tissue is the deepest layer of your skin. The prefix “sub” comes from the Latin word meaning under, and the word cutaneous derives from the Latin word “cutis,” which means skin.

About lecanemab (generic name, brand name: LEQEMBI®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal ...